Japanese pharmaceutical company Daiichi Sankyo (Tokyo:4568) announced on Wednesday that the first patient has been dosed in a global phase 2 trial evaluating the efficacy and safety of DS-7300 in patients with pretreated extensive-stage small cell lung cancer (SCLC).
DS-7300 is a potential first-in-class B7-H3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Most patients with SCLC are diagnosed with extensive-stage disease and have a five-year survival rate as low as 3%, highlighting the significant unmet need for more effective treatment options, Daiichi Sankyo said.
The trial aims to evaluate the efficacy and safety of two doses (8 mg/kg or 12 mg/kg) of DS-7300 in patients with histologically or cytologically confirmed extensive-stage SCLC that received at least one prior line of platinum-based chemotherapy.
Approximately 80 patients will take part in the study across Asia, Europe and North America.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review